MGMA

INDUSTRIAL IMPACT, MEDICAL

Celularity | January 17, 2023

Celularity Inc., a biotechnology firm based in the United States that develops placental-derived allogenic cell treatments and biomaterials, and CH Trading Group LLC, an international import, export, and trading corporation, have agreed to an exclusive territorial distribution agreement. CH Trading Group will serve as the exclusive territorial distributor for halal-certified products previously announced by Celularity in over 100 countries. The product distribution agreement for...

MEDICAL

GE | June 20, 2022

With most hospitals around the world currently relying on manual “spot-checks” to monitor patient vitals, GE Healthcare unveils Portrait Mobile3, a wireless patient monitoring system that enables continuous monitoring throughout a patient’s stay. The system helps clinicians detect patient deterioration. Early detection of patient deterioration may help reduce length of stay and intensive care unit (ICU) admissions – and improve patient outcomes4. Portrait Mobile includes ...

Amagma Therapeutics | January 19, 2022

Amagma Therapeutics, a biotechnology company developing antibody therapeutics for inflammatory diseases, announced a license option agreement with Innovent Biologics, Inc. for up to three enzyme specific inhibitors derived from Amagma’s proprietary SEIZMIC™ Platform. Amagma’s SEIZMIC™ Platform leverages a structure-based approach to identify highly selective antibodies which inhibit dysregulated proteases and other enzymes of interest. The co...

MEDICAL

Helix | March 09, 2022

HealthPartners and leading genomics company, Helix, are launching myGenetics, a population genomics program that will provide important health information to families across Minnesota and surrounding states. The myGenetics program hopes to enroll more than 100,000 participants over four years. Genomic data generated will be integrated with patient health records and shared during their personal clinical care. Through the partnership, HealthPartners will be able to identify risk ea...